Dental Health in Viking Age Icelanders

The purpose of the study was to evaluate dental health in Iceland 1000 years ago. Fifty-one skulls were available for research. There were 1001 teeth present in the 51 available skeletons. There was significantly more tooth wear in the age group 36 years and older (p<0.05), than in the 18-to-35-year-old age group but no significant difference between sexes. The highest rate of tooth wear was found in first molars, and the lowest in third molars. Heavy tooth wear can be explained by consumption of acidic drinks and food in addition to coarse diet. The main cause of the wear was most likely coarse and rough diet, dried fish and meat

Prevalence of Torus Mandibularis in Viking Age Icelanders

Of 48 available crania dated older than 1104AD, from the archaeological site of Skeljastadir in Thorsardalur, Iceland, 24 (50%) had torus mandibularis. There was no sex difference observed. The prevalence is similar among other populations in the northern hemisphere from the same time period. According to a number of authors, environmental and functional factors, particularly high masticatory activity, play a predominant part in the etiology. People from artic- and subartic areas survived on an animal diet, mostly fish and meat, but people living further south in a more temperate climate had more of an agricultural diet. Higher prevalence was found in the age group above 36 years than in the group 35 years and below. The majority of the tori were small or medium in size. The most frequently occurring variant was the multiple bilateral form, followed by the multiple unilateral form. The prevalence of torus mandibularis in the study was much higher than found in modern Iceland

Using affordable materials from metallurgical industries in Oxygen Carrier Aided Combustion and Chemical-Looping Combustion

Oxygen carriers are solid oxides of transition metals that can be used to convert fuel in the absence of gaseous oxygen in a process called Chemical-Looping Combustion (CLC). The use of oxygen carriers makes it possible to produce undiluted CO2 without expensive gas separation. High-concentration CO2 is a requirement in carbon capture and storage (CCS), which is considered a promising path for climate change mitigation. Oxygen carriers can also be used as bed material in fluidized bed conversion, and in that case provides enhanced oxygen distribution in the furnace. The concept is called Oxygen Carrier Aided Combustion (OCAC), and has been implemented in several existing biomass-, or municipal solid waste-fired boilers with ilmenite as oxygen carrier. This thesis examines utilizing oxygen carriers for the conversion of biomass and waste-derived fuels. Such fuels contain reactive ash species, which cause operational problems in the boiler such as corrosion, bed agglomeration, and slagging. Historically, much of the CLC-research has been on synthetic oxygen carriers with high reactivity. However, since the lifetime is expected to become quite low due to contamination of ash, they are likely not economically viable with these low-grade fuels. Here, the focus instead is on low-cost materials. The situation in Sweden is quite unique, since affordable metal oxide particles are produced in large quantities in our metallurgical industries. Several products and by-products from these industries are potential oxygen carriers. This thesis summarizes and discusses the large-scale utilization of oxygen carriers for OCAC in Sweden. Ilmenite is the most studied oxygen carrier for this purpose, but some other low-cost materials have also been tested in semi-industrial scale. The general findings are that implementing OCAC in already existing fluidized bed boilers is possible and enables a decrease in air-to-fuel ratio. Since biomass and waste fuels have complex and reactive ash compositions, they react with, and affect the lifetime of oxygen carriers. This thesis, therefore, also discusses ash interactions with some low-cost materials. Potassium is considered the most problematic ash element. Potassium is reactive with bed material and causes deposit formation and corrosion on the boiler, among other problems. Fixed bed interaction experiments have been conducted in this work with different potassium salts and oxygen carriers to study the changes in the materials with respect to composition and reactivity. Two by-products from steelmaking (LD-slag and iron mill scale) were studied in fixed bed interactions experiments. Also, as part of the work, a new lab-scale method which allows for improved experiments in a fluidized bed reactor has been developed. The method was used to study the effect of the accumulation of potassium on reactivity and fluidization of oxygen carriers. The study was conducted with ilmenite as oxygen carrier and K2CO3 as ash model compound. The addition of K2CO3 caused defluidization in ilmenite and diffusion of K into the particles

Oxygen Carrier Aided Combustion in Fluidized Bed Boilers in Sweden - Review and Future Outlook with Respect to Affordable Bed Materials

Oxygen carriers are metal oxide particles that could potentially enhance both fuel conversion and heat distribution in fluidized bed combustion, resulting in e.g., lowered emissions of unconverted species and better possibilities to utilize low‐grade fuels. A related technology based on fluidized beds with oxygen carriers can separate CO2 without large energy penalties. These technologies are called oxygen carrier aided combustion (OCAC) and chemical‐looping combustion (CLC), respectively. In the past few years, a large number of oxygen carriers have been suggested and evaluated for these purposes, many of which require complex production processes making them costly. Affordable metal oxide particles are, however, produced in large quantities as products and byproducts in the metallurgical industries. Some of these materials have properties making them potentially suitable to use as oxygen carriers. Uniquely for Sweden, the use of oxygen carriers in combustion have been subject to commercialization. This paper reviews results from utilizing low‐cost materials emerging from metallurgical industries for conversion of biomass and waste in semi‐commercial and commercial fluidized bed boilers in Sweden. The paper further goes on to discuss practical aspect of utilizing oxygen carriers, such as production and transport within the unique conditions in Sweden, where biomass and waste combustion as well as metallurgical industries are of large scale. This study concludes that utilizing metal oxides in this way could be technically feasible and beneficial to both the boiler owners and the metallurgical industries

Changes in macrophage phenotype and induction of epithelial‐to‐mesenchymal transition genes following acute Achilles tenotomy and repair

Tendon injuries occur frequently in physically active individuals, but the clinical outcomes for these injuries can be poor. In many injured tissues the repair process is orchestrated by two types of cells, macrophages and fibroblasts. Macrophages, which have both pro‐inflammatory (M1) and anti‐inflammatory (M2) phenotypes, can directly participate in tissue remodeling and direct the response of other cells through the secretion of cytokines and growth factors. In many organ systems, epithelial cells can trans‐differentiate into fibroblasts, which can then regenerate damaged ECM. This process is triggered via activation of epithelial‐to‐mesenchymal transition (EMT) signaling programs. Most tendons are surrounded by sheets of epithelial cells, and these tissue layers could provide a source of fibroblasts to repair injured tendons. To gain greater insight into the biology of tendon repair, we performed a tenotomy and repair in Achilles tendons of adult rats and determined changes in macrophage phenotype, and ECM‐ and EMT‐related genes over a 4‐week time course. The results from this study suggest that changes in macrophage phenotype and activation of EMT‐related programs likely contribute to the degradation and subsequent repair of injured tendon tissue. © 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:944–951, 2014.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106967/1/jor22624.pd

Association between the rs6950982 polymorphism near the SERPINE1 gene and blood pressure and lipid parameters in a high-cardiovascular-risk population: interaction with Mediterranean diet

The SERPINE1 (serpin peptidase inhibitor, clade E, member 1) gene, better known by its previous symbol PAI-1 (plasminogen activator inhibitor 1), has been associated with cardiovascular phenotypes with differing results. Our aim was to examine the association between the rs6950982 (G > A) near the SERPINE1 gene, blood pressure (BP) and plasma lipid concentrations as well as the modulation of the polymorphism effects by adherence to Mediterranean diet (AMD). We studied 945 high-cardiovascular-risk subjects. Biochemical, clinical, dietary and genetic data (rs6950982) were obtained. We also determined the common rs1799768 (4G/5G), for checking independent effects. AMD was measured by a validated questionnaire, and four groups were considered. rs6950982 (A > G) and rs1799768 (4G/5G) were only in moderate–low linkage disequilibrium (D′ = 0.719; r2 = 0.167). The most significant associations we obtained were with rs6950982 (A > G). In males, the G allele was nominally associated with higher diastolic BP (AA: 81.5 ± 10.9, AG: 82.1 ± 11.4, GG: 85.7 ± 10.5 mmHg; Padditive = 0.030) and systolic BP (AA + AG: 141.4 ± 6.9 mmHg vs. GG: 149.8 ± 8.0 mmHg; Precessive = 0.036). In the whole population, the rs6950982 was also associated with plasma lipids. Subject with the G allele presented higher total cholesterol (Padditive = 0.016, Precessive = 0.011), low-density lipoprotein cholesterol (Padditive = 0.032, Precessive = 0.031) and triglycerides (Padditive = 0.040, Precessive = 0.029). AMD modulated the effect of rs6950982 on triglyceride concentrations (P for interaction = 0.036). Greater AMD reduced the higher triglyceride concentrations in GG subjects. No significant interactions were found for the other parameters. The rs6950982 was associated with higher BP in men and higher triglycerides in the whole population, this association being modulated by AMD

Multivesicular exocytosis in rat pancreatic beta cells

AIMS/HYPOTHESIS: To establish the occurrence, modulation and functional significance of compound exocytosis in insulin-secreting beta cells. METHODS: Exocytosis was monitored in rat beta cells by electrophysiological, biochemical and optical methods. The functional assays were complemented by three-dimensional reconstruction of confocal imaging, transmission and block face scanning electron microscopy to obtain ultrastructural evidence of compound exocytosis. RESULTS: Compound exocytosis contributed marginally (&lt;5% of events) to exocytosis elicited by glucose/membrane depolarisation alone. However, in beta cells stimulated by a combination of glucose and the muscarinic agonist carbachol, 15-20% of the release events were due to multivesicular exocytosis, but the frequency of exocytosis was not affected. The optical measurements suggest that carbachol should stimulate insulin secretion by ∼40%, similar to the observed enhancement of glucose-induced insulin secretion. The effects of carbachol were mimicked by elevating [Ca(2+)](i) from 0.2 to 2 μmol/l Ca(2+). Two-photon sulforhodamine imaging revealed exocytotic events about fivefold larger than single vesicles and that these structures, once formed, could persist for tens of seconds. Cells exposed to carbachol for 30 s contained long (1-2 μm) serpentine-like membrane structures adjacent to the plasma membrane. Three-dimensional electron microscopy confirmed the existence of fused multigranular aggregates within the beta cell, the frequency of which increased about fourfold in response to stimulation with carbachol. CONCLUSIONS/INTERPRETATION: Although contributing marginally to glucose-induced insulin secretion, compound exocytosis becomes quantitatively significant under conditions associated with global elevation of cytoplasmic calcium. These findings suggest that compound exocytosis is a major contributor to the augmentation of glucose-induced insulin secretion by muscarinic receptor activation

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline